Financials Oncolytics Biotech Inc. Nasdaq
Equities
ONCY
CA6823108759
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.99 USD | -0.52% |
|
-1.98% | -26.67% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 162.1 | 130.8 | 96.3 | 131 | 132.3 | 104.5 | - | - |
Enterprise Value (EV) 1 | 162.1 | 130.8 | 96.3 | 131 | 132.3 | 104.5 | 104.5 | 104.5 |
P/E ratio | -4.1 x | -5.39 x | -3.57 x | -5.16 x | -4.37 x | -3.45 x | -3.73 x | -11.6 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 105 x | 12.9 x | 3.1 x |
EV / Revenue | - | - | - | - | - | 105 x | 12.9 x | 3.1 x |
EV / EBITDA | -7.88 x | -5.23 x | -3.69 x | -4.94 x | -3.96 x | -2.5 x | -1.83 x | -1.19 x |
EV / FCF | - | -5.92 x | -4.24 x | -5.6 x | -4.65 x | -1.93 x | -1.67 x | -1.34 x |
FCF Yield | - | -16.9% | -23.6% | -17.9% | -21.5% | -51.9% | -59.8% | -74.8% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 26,358 | 43,319 | 55,027 | 59,029 | 73,914 | 76,311 | - | - |
Reference price 2 | 6.150 | 3.020 | 1.750 | 2.220 | 1.790 | 1.370 | 1.370 | 1.370 |
Announcement Date | 20-03-05 | 21-03-05 | 22-03-03 | 23-03-03 | 24-03-07 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 1 | 8.124 | 33.76 |
EBITDA 1 | -20.57 | -25.01 | -26.1 | -26.53 | -33.39 | -41.8 | -57.1 | -88.2 |
EBIT 1 | -20.69 | -26.12 | -26.23 | -26.92 | -33.79 | -39.28 | -38.96 | -7.444 |
Operating Margin | - | - | - | - | - | -3,927.92% | -479.56% | -22.05% |
Earnings before Tax (EBT) 1 | -33.12 | -22.51 | -26.25 | -24.75 | -27.66 | -34.06 | -38.96 | -28.86 |
Net income 1 | -33.1 | -22.51 | -26.3 | -24.84 | -27.75 | -34.04 | -38.96 | -28.86 |
Net margin | - | - | - | - | - | -3,403.67% | -479.56% | -85.48% |
EPS 2 | -1.500 | -0.5600 | -0.4900 | -0.4300 | -0.4100 | -0.3977 | -0.3674 | -0.1178 |
Free Cash Flow 1 | - | -22.1 | -22.72 | -23.41 | -28.46 | -54.3 | -62.55 | -78.2 |
FCF margin | - | - | - | - | - | -5,430% | -769.98% | -231.65% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20-03-05 | 21-03-05 | 22-03-03 | 23-03-03 | 24-03-07 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 1.2 | - | - |
EBITDA 1 | -7.432 | -6.213 | -5.949 | -5.962 | -8.409 | -6.637 | -7.064 | -10.94 | -8.742 | -8.603 | -9.9 | -11 | -14.1 | - | - |
EBIT 1 | -7.455 | -6.31 | -6.046 | -6.06 | -8.508 | -6.734 | -7.16 | -11.05 | -8.849 | -8.726 | -9.173 | -9.766 | -11.6 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -966.27% | - | - |
Earnings before Tax (EBT) 1 | -7.709 | -6.779 | -5.07 | -4.405 | -8.498 | -6.437 | -7.394 | -9.918 | -3.906 | -6.894 | -8.823 | -9.32 | -9.346 | - | - |
Net income 1 | -7.751 | -6.779 | -5.095 | -4.407 | -8.554 | -6.437 | -7.441 | -9.925 | -3.949 | -6.894 | -8.823 | -9.32 | -9.346 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -778.81% | - | - |
EPS 2 | -0.1400 | -0.1200 | -0.0900 | -0.0800 | -0.1500 | -0.1000 | -0.1200 | -0.1400 | -0.0500 | -0.0900 | -0.1022 | -0.1078 | -0.0895 | -0.1050 | -0.1100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 22-03-03 | 22-05-05 | 22-08-11 | 22-11-07 | 23-03-03 | 23-05-05 | 23-08-14 | 23-11-03 | 24-03-07 | 24-05-09 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -22.1 | -22.7 | -23.4 | -28.5 | -54.3 | -62.6 | -78.2 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share 2 | - | -0.5500 | -0.4200 | -0.4000 | -0.4200 | -0.4100 | - | - |
Capex 1 | 0.01 | 0.03 | 0.29 | 0.06 | 0.01 | 0.5 | 0.5 | 5.5 |
Capex / Sales | - | - | - | - | - | 50% | 6.15% | 16.29% |
Announcement Date | 20-03-05 | 21-03-05 | 22-03-03 | 23-03-03 | 24-03-07 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 44.87B | |
-10.33% | 37.8B | |
+40.54% | 37.61B | |
+29.36% | 31.32B | |
-8.44% | 27.4B | |
+12.45% | 26.32B | |
+44.19% | 14.07B | |
+31.93% | 12.5B | |
-7.67% | 11.23B |
- Stock Market
- Equities
- ONC Stock
- ONCY Stock
- Financials Oncolytics Biotech Inc.